Earnings Feed
Start Free
Vir Biotechnology, Inc.·4

Feb 24, 7:09 PM ET

De Backer Marianne 4

4 · Vir Biotechnology, Inc. · Filed Feb 24, 2026

Insider Transaction Report

Form 4
Period: 2026-02-22
Vir Biotechnology, Inc.VIR
De Backer Marianne
DirectorChief Executive Officer
Transactions
  • Award

    Common Stock

    [F1]
    2026-02-22+285,000→ 1,054,505 total
  • Sale

    Common Stock

    [F2]
    2026-02-23$7.45/sh−19,039$141,894→ 1,035,466 total
  • Award

    Stock Option (Right to Buy)

    [F4]
    2026-02-22+570,000→ 570,000 total
    Exercise: $7.56Exp: 2036-02-21→ Common Stock (570,000 underlying)
Holdings

  • Common Stock

    [F3]
    (indirect: See Footnote)
    53,118
Footnotes (4)
  • [F1]Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
  • [F2]Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of RSUs. The sale does not represent a discretionary trade by the Reporting Person.
  • [F3]The shares are held in the name of the Ureel-De Backer Family Trust, of which the Reporting Person and her spouse are Trustees.
  • [F4]25% of the shares subject to the stock option will vest and become exercisable on February 22, 2027, and the remaining shares will vest in 36 equal monthly installments thereafter.
Signature
/s/ Vanina de Verneuil, Attorney-In-Fact|2026-02-24

Documents

1 file
  • 4
    wk-form4_1771978165.xmlPrimary

    FORM 4